CD19 and congenital rubella syndrome: Tocilizumab, an IL-6 receptor antagonist, manages severe CRS from CAR-T cells without harming T cells, while blinatumomab, a bispecific antibody that redirects effector T cells to B cells with its anti-CD3 and anti-CD19 arms, aims to prevent CRS through strategies such as disease reduction, corticosteroids, and dose adjustment [13].